WaveMan
WaveMan · Company
CORT · Corcept Therapeutics Inc
> Search tickers & screens ⌘K
LIVE
← All companies

CORT Corcept Therapeutics (CORT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001088856
Quote by TradingView
Form 144 · 11
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
276
13F, latest reported quarter
Conversions, 180 days
29
Codes C/M, not in net · $10.3M priced

What the filings say about CORT

Insiders, 180 days
-$83.3M net sold
10 sellers · 38% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$59.6M
11 notices

Corcept Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, CORCEPT THERAPEUTICS INC insiders sold a net $83.3M of stock across 310 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
WILSON JAMES N
Director
SELL
2026-10-16 SECtraded 2026-10-15
6,654
$761.7K
-22.3%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Sep 15, 2026.
  • The trade is 0.6% of the 1,057,889 shares held after it.
  • 3 other insiders sold within 30 days.
  • 276 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director WILSON JAMES N sold about $761.7K of CORT under a 10b5-1 plan on Oct 15, 2026; 3 other insiders sold within 30 days and 276 funds added in the latest 13F quarter.
WILSON JAMES N
Director
SELL
2026-10-16 SECtraded 2026-10-15
3,046
$351.5K
-22.3%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Sep 15, 2026.
  • The trade is 0.3% of the 1,054,843 shares held after it.
  • 3 other insiders sold within 30 days.
  • 276 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director WILSON JAMES N sold about $351.5K of CORT under a 10b5-1 plan on Oct 15, 2026; 3 other insiders sold within 30 days and 276 funds added in the latest 13F quarter.
WILSON JAMES N
Director
SELL
2026-10-16 SECtraded 2026-10-15
300
$34.9K
-22.3%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Sep 15, 2026.
  • The trade is 0.0% of the 1,054,543 shares held after it.
  • 3 other insiders sold within 30 days.
  • 276 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director WILSON JAMES N sold about $34.9K of CORT under a 10b5-1 plan on Oct 15, 2026; 3 other insiders sold within 30 days and 276 funds added in the latest 13F quarter.
Maduck Sean
See Remarks
SELL
2026-10-05 SECtraded 2026-10-02
15,843
$1.8M
-27.1%
Context
  • 67 earlier Form 4 trades (code P or S) here by this insider (67 sales), the last on Oct 1, 2026.
  • The trade is 84.8% of the 18,682 shares held after it.
  • 3 other insiders sold within 30 days.
  • 276 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Maduck Sean sold about $1.8M of CORT under a 10b5-1 plan on Oct 2, 2026; 3 other insiders sold within 30 days and 276 funds added in the latest 13F quarter.
Maduck Sean
See Remarks
SELL
2026-10-05 SECtraded 2026-10-02
8,744
$1.0M
-27.1%
Context
  • 67 earlier Form 4 trades (code P or S) here by this insider (67 sales), the last on Oct 1, 2026.
  • The trade is 88.0% of the 9,938 shares held after it.
  • 3 other insiders sold within 30 days.
  • 276 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Maduck Sean sold about $1.0M of CORT under a 10b5-1 plan on Oct 2, 2026; 3 other insiders sold within 30 days and 276 funds added in the latest 13F quarter.
310 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 305 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$83.3M over 180 days
-$53.9M over 90 days
below 97% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
276 funds bought in last quarter
more than 94% of Pharma & Biotech
Revenue
+12.8% year over year
more than 62% of Pharma & Biotech
Margin
13.1% net margin
more than 83% of Pharma & Biotech
Buybacks
$172.9M repurchased, FY to 2025-12-31
more than 74% of Pharma & Biotech
Short interest
8.8% of the float short (float per yahoo 2026-10-26) · 3.6 days to cover · settled 2026-09-30
more than 63% of Pharma & Biotech
The situation: each line is one rule over one dataset
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Oct 16Director WILSON JAMES N sold $1.1M under a 10b5-1 plan (Oct 15)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 5See Remarks Maduck Sean sold $2.9M under a 10b5-1 plan (3 trades, Oct 1 to Oct 2)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 5See Remarks Lyon Joseph Douglas sold $1.2M under a 10b5-1 plan (3 trades, Oct 1 to Oct 2)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 5President, Oncology Vieira Roberto Wandenkolk sold $967.4K under a 10b5-1 plan (Oct 2)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 1Officer Lyon Joseph Douglas filed to sell $1.2M by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch CORT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+19.4%12M
-56%-14%+28%+69%2025-102025-122026-022026-042026-062026-082026-10 2026-08-18 · MAHONEY DAVID L sold $10.8M2026-05-27 · Maduck Sean sold $3.6M2026-08-26 · Park Kimberly sold $3.3M2025-12-01 · BELANOFF JOSEPH K sold $3.2M2026-08-25 · Maduck Sean sold $3.1M2026-06-01 · Mokari Atabak sold $2.8M2026-09-02 · Vieira Roberto Wandenkolk sold $2.6M2026-09-02 · Vieira Roberto Wandenkolk sold $2.6M2026-07-15 · Mokari Atabak sold $2.5M2026-03-17 · BAKER G LEONARD JR bought $2.5M2026-08-03 · Maduck Sean sold $2.3M2026-05-01 · BELANOFF JOSEPH K sold $2.0M2026-10-02 · Maduck Sean sold $1.8M2026-07-30 · Mokari Atabak sold $1.8M2026-07-07 · Guyer William sold $1.8M2026-06-17 · MAHONEY DAVID L sold $1.7M2026-07-30 · Mokari Atabak sold $1.6M2026-06-15 · Mokari Atabak sold $1.6M2025-12-01 · Maduck Sean sold $1.6M2025-12-02 · Guyer William sold $1.5M2025-11-03 · Maduck Sean sold $1.5M2026-06-01 · Maduck Sean sold $1.5M2026-06-02 · Guyer William sold $1.4M2026-05-27 · Maduck Sean sold $1.4M2026-09-01 · Maduck Sean sold $1.3M2026-03-25 · BELANOFF JOSEPH K sold $1.3M2026-08-10 · Guyer William sold $1.3M2026-09-01 · Maduck Sean sold $1.3M2026-08-17 · Robb Gary Charles sold $1.2M2025-11-05 · BELANOFF JOSEPH K sold $1.1M2026-05-05 · Guyer William sold $1.0M2026-10-02 · Maduck Sean sold $1.0M2026-07-01 · Maduck Sean sold $998.0K2025-11-05 · Guyer William sold $995.7K2026-07-30 · Mokari Atabak sold $975.0K2026-07-30 · Mokari Atabak sold $971.9K2026-07-01 · Maduck Sean sold $962.8K2026-07-30 · Mokari Atabak sold $957.9K2026-06-15 · Mokari Atabak sold $896.9K2026-06-01 · BELANOFF JOSEPH K sold $895.3K2026-09-14 · Lyon Joseph Douglas sold $885.3K2026-08-18 · MAHONEY DAVID L sold $838.7K2026-10-01 · Lyon Joseph Douglas filed to sell $1.2M2026-09-15 · WILSON JAMES N filed to sell $3.3M2026-09-14 · Lyon Joseph Douglas filed to sell $1.1M2026-09-02 · Vieira Roberto Wandenkolk filed to sell $8.3M2026-08-26 · KIMBERLY PARK filed to sell $3.3M2026-08-25 · Maduck Sean filed to sell $22.0M2026-08-18 · MAHONEY DAVID L filed to sell $12.2M2026-08-17 · Robb Gary Charles filed to sell $1.2M2026-08-04 · Guyer William filed to sell $2.3M2026-08-03 · Lyon Joseph Douglas filed to sell $175.8K2026-07-30 · Mokari Atabak filed to sell $4.6M2026-07-07 · Guyer William filed to sell $1.9M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CORT: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
12,432,023 sh
$1.1B
RENAISSANCE TECHNOLOGIES LLC
5,261,628 sh
$457.5M
VANGUARD PORTFOLIO MANAGEMENT LLC
5,044,638 sh
$438.6M
VANGUARD CAPITAL MANAGEMENT LLC
4,172,482 sh
$362.8M
Parallel Advisors, LLC
3,962,177 sh
$344.5M

Congress trades in CORT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CORT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Lyon Joseph Douglas
Filed 2026-10-01
$1.2M
WILSON JAMES N
Filed 2026-09-15
$3.3M
Lyon Joseph Douglas
Filed 2026-09-14
$1.1M
Vieira Roberto Wandenkolk
Filed 2026-09-02
$8.3M
KIMBERLY PARK
Filed 2026-08-26
$3.3M

CORT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Tanaka Growth Fund
$3.6M position · as of 2026-05-31
9.1%
First Trust NYSE Arca Biotechnology Index Fund
$157.5M position · as of 2026-06-30
5.6%
F/m Emerald Special Situations ETF
$1.8M position · as of 2026-07-31
5.4%
Invesco Pharmaceuticals ETF
$23.4M position · as of 2026-07-31
5.0%
F/m Emerald Life Sciences Innovation ETF
$5.0M position · as of 2026-05-31
4.8%
Invesco S&P SmallCap Health Care ETF
$4.6M position · as of 2026-05-31
3.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
33 registered trials, 6 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
15
Phase 1
0 active
8
Phase 2
4 active
4
Phase 3
1 active
1
Phase 4
0 active
3
Not applicable
0 active
2
Multi-phase
1 active
What changed recently
Evaluating the Pharmacokinetics and Safety of Miricorilant
2026-10-17 · Recruiting → Completed
Phase 1
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
2026-10-01 · Completion moved 2026-08 → 2026-08-13
Phase 1
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
2026-10-01 · Active Not Recruiting → Completed
Phase 1
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepa
2026-09-29 · Active Not Recruiting → Completed
Phase 2
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Gr
2026-09-26 · Completion moved 2025-03-24 → 2025-03-31
Phase 3
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
2026-09-25 · Recruiting → Active Not Recruiting
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Dr. Belanoff
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$15.3M
$14.8M
$6.3M
+33%
+20%
2024
$9.9M
$22.8M
$4.0M
+93%
-9%
2023
$9.3M
$15.8M
$3.9M
+24%
-8%
2022
$7.4M
$9.6M
$3.0M
-22%
-11%
2021
$11.0M
$4.3M
$5.3M
-24%
-1%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $83.3M sold by insiders over 180 days, 276 funds added last quarter, $59.6M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CORT financials

Revenue growth
+12.8%
XBRL, annual
Net margin
13.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$830.8M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+6.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$106.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term 2017-12-31 (103 months older than the period end) plus current 2017-12-31 (103 months older than the period end); equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
+8.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+6.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
effective tax rate -109%, not meaningful
Return on capital employed
+0.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
207.45x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$9.3B
market value at close 2026-10-26 on 2026-07-22 shares, plus long-term 2017-12-31 (103 months older than the period end) plus current 2017-12-31 (103 months older than the period end), minus cash 2026-06-30
FCF yield
+1.1%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing EPS growth -63%, PEG needs growth
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$761.4M$675.0M$482.4M$401.9M
Operating income$44.8M$137.0M$107.3M$112.6M
Net income$99.7M$141.2M$106.1M$101.4M
EPS (diluted)0.821.230.940.87
Operating cash flow$142.0M$198.3M$126.7M$120.3M
Cash$120.5M$127.7M$135.6M$66.3M
Buybacks$172.9M$15.7M$0$0
SEC XBRL, fiscal years, as known on 2026-10-28

CORT Stock Sonar score 6/7 axes

Find similar shapesCompare

CORT ranks highest on financial health (99th percentile) and institutional and government (94th), and lowest on insider conviction (2nd), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
85
Inputs
  • Return on equity+8.2% · 84 pct, sector of 545
  • Return on assets+6.5% · 86 pct, sector of 691
  • Return on invested capitaleffective tax rate -109%, not meaningful
  • Return on capital employed+0.9% · 86 pct, sector of 576
Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 352
  • Cash flow to debtno debt to cover
Growth
62
Inputs
  • Revenue growth, YoY+12.8% · 62 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
2
Inputs
  • Net Form 4 buying (codes P and S), 180d-$49.4M · 4 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
94
Inputs
  • Funds adding, latest quarter276 · 94 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
25
Inputs
  • Short interest, % of float+8.8% · 43 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+29.5% · 8 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CORT filings, in plain words

Are Corcept Therapeutics insiders buying or selling CORT?

In the 180 days to 2026-10-28, Corcept Therapeutics insiders were net sellers, a net $83.3M across purchases and sales reported on Form 4, by 10 sellers.

Are there planned insider sales of CORT?

Yes. 11 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $59.6M of stock; the latest, by Lyon Joseph Douglas, was filed 2026-10-01.

Read the full summary

In the 180 days to 2026-10-28, Corcept Therapeutics insiders were net sellers of CORT, a net $83.3M across purchases and sales reported on Form 4 by 10 sellers. 38% of the 89 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 11 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $59.6M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies